These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21524244)

  • 41. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet.
    Apostolou T; Damianou L; Kotsiev V; Drakopoulos S; Hadjiconstantinou V
    Clin Nephrol; 2006 May; 65(5):374-7. PubMed ID: 16724661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
    Goodman WG
    Curr Opin Nephrol Hypertens; 2005 Jul; 14(4):355-60. PubMed ID: 15931004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cinacalcet effect on severe hyperparathyroidism.
    Al Saran K; Sabry A; Yehia A; Molhem A
    Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):867-71. PubMed ID: 20814122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
    Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD
    J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism.
    Untch BR; Barfield ME; Dar M; Dixit D; Leight GS; Olson JA
    Surgery; 2007 Dec; 142(6):1022-6. PubMed ID: 18063090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Significance of point of no return in therapeutic strategy for treatment of renal osteodystrophy; from histopathological findings].
    Koiwa F; Hirose M
    Clin Calcium; 2004 Sep; 14(9):46-52. PubMed ID: 15577109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.
    Peacock M; Bilezikian JP; Klassen PS; Guo MD; Turner SA; Shoback D
    J Clin Endocrinol Metab; 2005 Jan; 90(1):135-41. PubMed ID: 15522938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
    Hanba Y; Ooura M; Negi S; Shigematsu T
    Clin Calcium; 2008 Jan; 18(1):81-8. PubMed ID: 18175876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics of secondary hyperparathyroidism in vitamin D-deficient dogs.
    Hendy GN; Stotland MA; Grunbaum D; Fraher LJ; Loveridge N; Goltzman D
    Am J Physiol; 1989 Jun; 256(6 Pt 1):E765-72. PubMed ID: 2735402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region.
    Raef H; Ingemansson S; Sobhi S; Sultan A; Ahmed M; Chaudhry M
    J Endocrinol Invest; 2004 Oct; 27(9):807-12. PubMed ID: 15648543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM; Coyne D
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients.
    Peacey SR; Wright D; Harries MJ
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):603-6. PubMed ID: 15521963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
    Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amino terminal cleavage of PTH(1-84) to PTH(7-84) is regulated by serum calcium concentration via calcium-sensing receptor in hemodialysis patients.
    Koshikawa M; Nishiguchi K; Yorifuji S; Shimazu K; Takaori K; Mori K; Eguchi E; Okada K; Tanaka A; Kuwahara T
    Clin Exp Nephrol; 2010 Jun; 14(3):233-8. PubMed ID: 20127382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.